Archive for October, 2017

Neil Sampson meets DeHeng founder Dr Wang Li on recent trip to China

30/10/2017
Neil Sampson met DeHeng (DHH Law Firm) Founder, Dr Wang Li on his recent visit to China, following on from DeHeng's visit to Rosenblatt back in September.

Neil Sampson met DeHeng (DHH Law Firm) Founder, Dr Wang Li on his recent visit to China, following on from DeHeng’s visit to Rosenblatt back in September.

Rosenblatt acted for Revelan Holdings Limited and the wider Revelan Group, a group of property investment and development companies, on a group reorganisation, redemption of intra-group loans and a new equity investment by Ares Management.

17/10/2017
Rosenblatt has acted for Revelan Holdings Limited and the wider Revelan Group, a group of property investment and development companies, in connection with a sale by one of the Founding Partners coup

Rosenblatt has acted for Revelan Holdings Limited and the wider Revelan Group, a group of property investment and development companies, in connection with a sale by one of the Founding Partners coupled with an equity investment by Geranium Holdings Sarl in Revelan Holdings Limited, a share and group reorganisation, bonus issue and redemption of loan notes, together with the putting in place of intra-group subordinated loans, a put and call option and effecting changes to directorships within the Revelan Group. The Rosenblatt team provided both corporate and banking advice in relation to the transaction which successfully completed on 6 October 2017.

The Rosenblatt team was led by Jon Lovitt (Corporate Partner) who was assisted by Sophie Lang (Corporate Solicitor), David Sachs (Head of Banking), Tom Driscoll (Banking Solicitor) and Verity Ingle (Trainee Solicitor).

Rosenblatt supports Target Ovarian Cancer’s TAKE OVAR campaign

12/10/2017
Funding for ovarian cancer research has dropped by a third in the past five years. This comes at a time of a projected rise in the incidence rates of the disease, meaning UK women are facing a demogr

Funding for ovarian cancer research has dropped by a third in the past five years. This comes at a time of a projected rise in the incidence rates of the disease, meaning UK women are facing a demographic ‘time bomb’ in ovarian cancer. Target Ovarian Cancer’s new campaign launching today, says enough is enough. It’s time to TAKE OVAR.

Join the campaign –www.targetovariancancer.org.uk/take-ovar-ovarian-cancer-research-awareness-and-support

  • contact

    To contact us please complete this form

e-Bulletins